Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Research Council grant · Running

MYSTIC MYC suppression through innovative chemistry

Coordinator
Universiteit Leiden, Netherlands
Runs
1 May 2025 to 31 October 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101213005

What the project is doing

In the project's own words, from its summary on CORDIS.

MYSTIC aims to revolutionize cancer treatment by advancing HeloMYC, a novel cell-penetrating protein therapeutic that targets the oncogenic transcription factor MYC. Developed using our innovative reCHEMbinant platform, HeloMYC represents a breakthrough in addressing an ""undruggable"" intracellular target, combining the specificity of protein therapeutics with enhanced cell penetration and stability. MYC, implicated in over 50% of human cancers, has long been considered an elusive target due to its complex protein-protein and protein-nucleic acid interactions and lack of druggable pockets.

HeloMYC is a protein based MYC inhibitor that overcomes these challenges and through strategic chemical modifications achieves potent intracellular activity against MYC-driven transcription in cancer cells in preliminary studies. This 18 months project will focus on three key objectives: advancing HeloMYC's preclinical development

Topics

Who is involved

OrganisationCityCountryRole
Universiteit LeidenLeidenNetherlandsCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI